A Phase III Study Comparing Adjuvant Chemotherapy Consisting of Capecitabine/Oxaliplatin Versus Surgery Alone in Patients With Stage II (T1N2, T2N1, T3N0), IIIa (T2N2, T3N1, T4N0) and IIIb (T3N2) Gastric Adenocarcinoma

Trial Profile

A Phase III Study Comparing Adjuvant Chemotherapy Consisting of Capecitabine/Oxaliplatin Versus Surgery Alone in Patients With Stage II (T1N2, T2N1, T3N0), IIIa (T2N2, T3N1, T4N0) and IIIb (T3N2) Gastric Adenocarcinoma

Completed
Phase of Trial: Phase III

Latest Information Update: 14 Jun 2016

At a glance

  • Drugs Capecitabine (Primary) ; Oxaliplatin (Primary)
  • Indications Gastric cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 24 Sep 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 23 Feb 2010 Status changed from active, no longer recruiting to recruiting as reported by Roche record.
    • 20 Jun 2009 Additional trial location (South Korea) added as reported by Roche record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top